{"id":53373,"date":"2023-01-27T14:02:29","date_gmt":"2023-01-27T13:02:29","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/quince-therapeutics-completes-the-sale-of-legacy-protease-inhibitor-portfolio-to-lighthouse-pharmaceuticals\/"},"modified":"2023-01-27T14:02:29","modified_gmt":"2023-01-27T13:02:29","slug":"quince-therapeutics-completes-the-sale-of-legacy-protease-inhibitor-portfolio-to-lighthouse-pharmaceuticals","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/quince-therapeutics-completes-the-sale-of-legacy-protease-inhibitor-portfolio-to-lighthouse-pharmaceuticals\/","title":{"rendered":"Quince Therapeutics Completes the Sale of Legacy Protease Inhibitor Portfolio to Lighthouse Pharmaceuticals"},"content":{"rendered":"<div>\n<p>SOUTH SAN FRANCISCO, Calif.&#8211;(BUSINESS WIRE)&#8211;<a href=\"https:\/\/twitter.com\/search?q=%24QNCX&amp;src=ctag\" target=\"_blank\" rel=\"noopener\">$QNCX<\/a>&#8211;Quince Therapeutics, Inc. (Nasdaq: QNCX), a biopharmaceutical company advancing innovative precision therapeutics targeting debilitating and rare diseases, announced the sale of the company\u2019s legacy small molecule protease inhibitor portfolio, including COR588, COR388, COR852, and COR803, pursuant to an asset purchase agreement with Lighthouse Pharmaceuticals, Inc., an entity co-founded by Casey Lynch, former chief executive officer of Quince\u2019s predecessor company Cortexyme.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20230127005086\/en\/1528430\/5\/Quince_Therapeutics_Logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230127005086\/en\/1528430\/21\/Quince_Therapeutics_Logo.jpg\"><\/a><\/p>\n<p>\nLead compound COR588 is a selective, oral small molecule inhibitor of lysine-gingipain that is Phase 2 ready for further evaluation in the treatment of Alzheimer\u2019s disease with mild to moderate dementia and biomarker evidence of <i>P. gingivalis <\/i>infection. Precision targeting of gingipains with small molecule inhibitors represents an innovative therapeutic approach to addressing <i>P. gingivalis, <\/i>a bacterium associated with dementia and other degenerative and inflammatory disorders.\n<\/p>\n<p>\n\u201cThis transaction represents the fulfillment of our previously stated objective to out-license Quince\u2019s legacy protease inhibitor portfolio,\u201d said Dirk Thye, M.D., Quince\u2019s chief executive officer. \u201cWe are pleased to transfer these programs to Lighthouse as they have a tremendous amount of expertise, experience, and historical knowledge of the compounds and therapeutic area. Given the role of Lighthouse\u2019s principals in advancing the foundational science and clinical development related to these assets, we believe they are in a strong position to build upon the existing human and preclinical data to advance these compounds.\u201d\n<\/p>\n<p>\n\u201cThis acquisition enables the important continued development of gingipain inhibitors for dementia and other disorders,\u201d said Casey Lynch, Lighthouse Pharmaceutical\u2019s chief executive officer. \u201cInformed by the learnings from previous late-stage clinical studies, Lighthouse will move quickly to advance COR588 into key clinical studies to further validate this treatment paradigm and bring innovative treatments to patients.\u201d\n<\/p>\n<p>\nHighlights of the asset purchase agreement include:\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nLighthouse gains exclusive rights to develop, manufacture, and commercialize Quince\u2019s legacy protease inhibitor portfolio globally;\n<\/li>\n<li>\nProtease inhibitor portfolio includes lysine- and arginine-gingipain inhibitors COR588, COR388, COR852, in addition to COR803, which is a coronavirus 3CLpro targeted program with demonstrated <i>in vivo<\/i> efficacy;\n<\/li>\n<li>\nPotential for Quince to receive up to $150 million in regulatory and commercial milestones payments on a product-by-product basis, subject to conditions in the agreement;\n<\/li>\n<li>\nPotential tiered royalty rates on a product-by-product basis ranging from high single-digit to mid-teens of annual net sales related to the two existing clinical stage programs, and low single-digit royalties for the preclinical programs, subject to conditions in the agreement;\n<\/li>\n<li>\nShare of sublicense income or acquisition value of clinical and preclinical assets on a product-by-product basis; and\n<\/li>\n<li>\nQuince to receive a 7.5% ownership stake of Lighthouse Common stock with anti-dilution through the first $10 million raised.\n<\/li>\n<\/ul>\n<p>\nQuince expects to benefit from the reduction of more than $500,000 of annualized expenses associated with the operational and financial support of these protease inhibitor assets.\n<\/p>\n<p>\n<b>About Quince Therapeutics<\/b>\n<\/p>\n<p>\nQuince Therapeutics is focused on advancing innovative precision therapeutics targeting debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote more rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Quince\u2019s discovery pipeline is positioned for rapid expansion across multiple skeletal therapeutic indications to address underserved therapeutic areas with major, unmet medical needs, including osteogenesis imperfecta, fractures, spinal fusion, and other severe bone diseases. The company&#8217;s lead compound NOV004 is an anabolic peptide engineered to precisely target and concentrate at the bone fracture site, which preclinical studies demonstrate result in rapid increases in bone density, strength, and healing directly at the site of bone fracture. For more information, visit <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.quincetx.com&amp;esheet=53292265&amp;newsitemid=20230127005086&amp;lan=en-US&amp;anchor=www.quincetx.com&amp;index=1&amp;md5=20655dcae49f0200924b5019daa7581d\" rel=\"nofollow noopener\" shape=\"rect\">www.quincetx.com<\/a> and follow Quince Therapeutics on LinkedIn and @Quince_Tx on Twitter.\n<\/p>\n<p>\n<b>About Lighthouse Pharmaceuticals<\/b>\n<\/p>\n<p>\nLighthouse Pharmaceuticals is a clinical stage private biopharmaceutical company pioneering precision medicine approaches to major unmet medical needs based on expertise in small molecule protease inhibition. Lighthouse\u2019s lead program, LHP588, beginning Phase 2 clinical studies, targets a specific, infectious pathogen, <i>Porphyromonas gingivalis<\/i>, which is associated with chronic degenerative and inflammatory disorders including dementia, periodontal disease, atherosclerosis, and orodigestive cancers. For more information, visit <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.lighthousepharma.com%2F&amp;esheet=53292265&amp;newsitemid=20230127005086&amp;lan=en-US&amp;anchor=www.lighthousepharma.com&amp;index=2&amp;md5=7c5c7e5e7f58bec1fd414ac485320a7b\" rel=\"nofollow noopener\" shape=\"rect\">www.lighthousepharma.com<\/a>.\n<\/p>\n<p>\n<b>Forward-looking Statements<\/b>\n<\/p>\n<p>\nStatements in this news release contain \u201cforward-looking statements\u201d that are subject to substantial risks and uncertainties. Forward-looking statements contained in this news release may be identified by the use of words such as \u201canticipate,\u201d \u201cexpect,\u201d \u201cwill,\u201d \u201ccan,\u201d \u201cmay,\u201d \u201cshould,\u201d \u201cestimate,\u201d \u201cproject,\u201d \u201cpotential,\u201d \u201cencouraged,\u201d \u201cpositioned,\u201d or other similar words. Examples of forward-looking statements include, among others, the potential to realize expense reductions, and to receive royalties, sublicense license, acquisition value, milestone and other payments, if any, associated with the transaction with Lighthouse; clinical development and strategic development path and related timing for NOV004; the company\u2019s plans to pursue the strategic expansion of its development pipeline; the timing and success of the company\u2019s clinical trials and related data, including plans and the ability to initiate, conduct and\/or complete the Phase 1 clinical studies for NOV004 and advance to a lead indication; and the timing of announcements and updates relating to its clinical trials and related data; the potential therapeutic benefits, safety, and efficacy of the company\u2019s product candidate and discovery pipeline. Forward-looking statements are based on Quince Therapeutic\u2019s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict and could cause actual results to differ materially from what the company expects. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, but are not limited to, the risks and uncertainties described in the section titled \u201cRisk Factors\u201d in the company\u2019s Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 1, 2022, its Quarterly Report on Form 10-Q filed with the SEC on November 9, 2022, and other reports as filed with the SEC. Forward-looking statements contained in this news release are made as of this date, and Quince Therapeutics undertakes no duty to update such information except as required under applicable law.\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b>Media and Investor Contacts: <\/b>\n<\/p>\n<p>\nStacy Roughan<br \/>\n<br \/>Quince Therapeutics, Inc.<br \/>\n<br \/>Vice President, Corporate Communications &amp; Investor Relations<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;a&#105;l&#116;o&#x3a;i&#x72;&#64;&#x71;u&#x69;n&#x63;e&#x74;x&#x2e;c&#x6f;m\" rel=\"nofollow noopener\" shape=\"rect\">&#x69;&#114;&#x40;&#x71;&#117;&#x69;&#x6e;&#99;&#x65;&#x74;&#120;&#x2e;&#x63;o&#x6d;<\/a>\n<\/p>\n<p>\nCasey Lynch<br \/>\n<br \/>Chief Executive Officer<br \/>\n<br \/>Lighthouse Pharmaceuticals, Inc.<br \/>\n<br \/><a target=\"_blank\" href=\"m&#97;&#x69;&#x6c;t&#111;&#58;&#x69;&#x6e;f&#111;&#64;&#x6c;&#x69;g&#104;&#x74;&#x68;&#x6f;u&#115;&#x65;&#x70;h&#97;&#114;&#x6d;&#x61;&#46;&#99;&#111;&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">&#105;&#x6e;&#102;&#x6f;&#64;&#108;&#x69;&#103;&#x68;t&#x68;o&#117;&#x73;&#101;&#x70;h&#x61;&#x72;&#109;&#x61;&#46;&#x63;o&#109;<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>SOUTH SAN FRANCISCO, Calif.&#8211;(BUSINESS WIRE)&#8211;$QNCX&#8211;Quince Therapeutics, Inc. (Nasdaq: QNCX), a biopharmaceutical company advancing innovative precision therapeutics targeting debilitating and rare diseases, announced the sale of the company\u2019s legacy small molecule protease inhibitor portfolio, including COR588, COR388, COR852, and COR803, pursuant to an asset purchase agreement with Lighthouse Pharmaceuticals, Inc., an entity co-founded by Casey Lynch, &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/quince-therapeutics-completes-the-sale-of-legacy-protease-inhibitor-portfolio-to-lighthouse-pharmaceuticals\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-53373","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Quince Therapeutics Completes the Sale of Legacy Protease Inhibitor Portfolio to Lighthouse Pharmaceuticals - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/quince-therapeutics-completes-the-sale-of-legacy-protease-inhibitor-portfolio-to-lighthouse-pharmaceuticals\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Quince Therapeutics Completes the Sale of Legacy Protease Inhibitor Portfolio to Lighthouse Pharmaceuticals - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"SOUTH SAN FRANCISCO, Calif.&#8211;(BUSINESS WIRE)&#8211;$QNCX&#8211;Quince Therapeutics, Inc. (Nasdaq: QNCX), a biopharmaceutical company advancing innovative precision therapeutics targeting debilitating and rare diseases, announced the sale of the company\u2019s legacy small molecule protease inhibitor portfolio, including COR588, COR388, COR852, and COR803, pursuant to an asset purchase agreement with Lighthouse Pharmaceuticals, Inc., an entity co-founded by Casey Lynch, ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/quince-therapeutics-completes-the-sale-of-legacy-protease-inhibitor-portfolio-to-lighthouse-pharmaceuticals\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-27T13:02:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230127005086\/en\/1528430\/21\/Quince_Therapeutics_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/quince-therapeutics-completes-the-sale-of-legacy-protease-inhibitor-portfolio-to-lighthouse-pharmaceuticals\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/quince-therapeutics-completes-the-sale-of-legacy-protease-inhibitor-portfolio-to-lighthouse-pharmaceuticals\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Quince Therapeutics Completes the Sale of Legacy Protease Inhibitor Portfolio to Lighthouse Pharmaceuticals\",\"datePublished\":\"2023-01-27T13:02:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/quince-therapeutics-completes-the-sale-of-legacy-protease-inhibitor-portfolio-to-lighthouse-pharmaceuticals\\\/\"},\"wordCount\":1049,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/quince-therapeutics-completes-the-sale-of-legacy-protease-inhibitor-portfolio-to-lighthouse-pharmaceuticals\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230127005086\\\/en\\\/1528430\\\/21\\\/Quince_Therapeutics_Logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/quince-therapeutics-completes-the-sale-of-legacy-protease-inhibitor-portfolio-to-lighthouse-pharmaceuticals\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/quince-therapeutics-completes-the-sale-of-legacy-protease-inhibitor-portfolio-to-lighthouse-pharmaceuticals\\\/\",\"name\":\"Quince Therapeutics Completes the Sale of Legacy Protease Inhibitor Portfolio to Lighthouse Pharmaceuticals - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/quince-therapeutics-completes-the-sale-of-legacy-protease-inhibitor-portfolio-to-lighthouse-pharmaceuticals\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/quince-therapeutics-completes-the-sale-of-legacy-protease-inhibitor-portfolio-to-lighthouse-pharmaceuticals\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230127005086\\\/en\\\/1528430\\\/21\\\/Quince_Therapeutics_Logo.jpg\",\"datePublished\":\"2023-01-27T13:02:29+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/quince-therapeutics-completes-the-sale-of-legacy-protease-inhibitor-portfolio-to-lighthouse-pharmaceuticals\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/quince-therapeutics-completes-the-sale-of-legacy-protease-inhibitor-portfolio-to-lighthouse-pharmaceuticals\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/quince-therapeutics-completes-the-sale-of-legacy-protease-inhibitor-portfolio-to-lighthouse-pharmaceuticals\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230127005086\\\/en\\\/1528430\\\/21\\\/Quince_Therapeutics_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230127005086\\\/en\\\/1528430\\\/21\\\/Quince_Therapeutics_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/quince-therapeutics-completes-the-sale-of-legacy-protease-inhibitor-portfolio-to-lighthouse-pharmaceuticals\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Quince Therapeutics Completes the Sale of Legacy Protease Inhibitor Portfolio to Lighthouse Pharmaceuticals\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Quince Therapeutics Completes the Sale of Legacy Protease Inhibitor Portfolio to Lighthouse Pharmaceuticals - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/quince-therapeutics-completes-the-sale-of-legacy-protease-inhibitor-portfolio-to-lighthouse-pharmaceuticals\/","og_locale":"en_US","og_type":"article","og_title":"Quince Therapeutics Completes the Sale of Legacy Protease Inhibitor Portfolio to Lighthouse Pharmaceuticals - Pharma Trend","og_description":"SOUTH SAN FRANCISCO, Calif.&#8211;(BUSINESS WIRE)&#8211;$QNCX&#8211;Quince Therapeutics, Inc. (Nasdaq: QNCX), a biopharmaceutical company advancing innovative precision therapeutics targeting debilitating and rare diseases, announced the sale of the company\u2019s legacy small molecule protease inhibitor portfolio, including COR588, COR388, COR852, and COR803, pursuant to an asset purchase agreement with Lighthouse Pharmaceuticals, Inc., an entity co-founded by Casey Lynch, ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/quince-therapeutics-completes-the-sale-of-legacy-protease-inhibitor-portfolio-to-lighthouse-pharmaceuticals\/","og_site_name":"Pharma Trend","article_published_time":"2023-01-27T13:02:29+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230127005086\/en\/1528430\/21\/Quince_Therapeutics_Logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/quince-therapeutics-completes-the-sale-of-legacy-protease-inhibitor-portfolio-to-lighthouse-pharmaceuticals\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/quince-therapeutics-completes-the-sale-of-legacy-protease-inhibitor-portfolio-to-lighthouse-pharmaceuticals\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Quince Therapeutics Completes the Sale of Legacy Protease Inhibitor Portfolio to Lighthouse Pharmaceuticals","datePublished":"2023-01-27T13:02:29+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/quince-therapeutics-completes-the-sale-of-legacy-protease-inhibitor-portfolio-to-lighthouse-pharmaceuticals\/"},"wordCount":1049,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/quince-therapeutics-completes-the-sale-of-legacy-protease-inhibitor-portfolio-to-lighthouse-pharmaceuticals\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230127005086\/en\/1528430\/21\/Quince_Therapeutics_Logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/quince-therapeutics-completes-the-sale-of-legacy-protease-inhibitor-portfolio-to-lighthouse-pharmaceuticals\/","url":"https:\/\/pharma-trend.com\/en\/quince-therapeutics-completes-the-sale-of-legacy-protease-inhibitor-portfolio-to-lighthouse-pharmaceuticals\/","name":"Quince Therapeutics Completes the Sale of Legacy Protease Inhibitor Portfolio to Lighthouse Pharmaceuticals - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/quince-therapeutics-completes-the-sale-of-legacy-protease-inhibitor-portfolio-to-lighthouse-pharmaceuticals\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/quince-therapeutics-completes-the-sale-of-legacy-protease-inhibitor-portfolio-to-lighthouse-pharmaceuticals\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230127005086\/en\/1528430\/21\/Quince_Therapeutics_Logo.jpg","datePublished":"2023-01-27T13:02:29+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/quince-therapeutics-completes-the-sale-of-legacy-protease-inhibitor-portfolio-to-lighthouse-pharmaceuticals\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/quince-therapeutics-completes-the-sale-of-legacy-protease-inhibitor-portfolio-to-lighthouse-pharmaceuticals\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/quince-therapeutics-completes-the-sale-of-legacy-protease-inhibitor-portfolio-to-lighthouse-pharmaceuticals\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230127005086\/en\/1528430\/21\/Quince_Therapeutics_Logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230127005086\/en\/1528430\/21\/Quince_Therapeutics_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/quince-therapeutics-completes-the-sale-of-legacy-protease-inhibitor-portfolio-to-lighthouse-pharmaceuticals\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Quince Therapeutics Completes the Sale of Legacy Protease Inhibitor Portfolio to Lighthouse Pharmaceuticals"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53373","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=53373"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53373\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=53373"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=53373"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=53373"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}